Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with stable, moderate to severe hidradenitis suppurativa~* Negative Chest X-ray and PPD test at Screening. If participant has had a past ulcerative reaction to PPD placement and/or chest X-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy.~* Ability to administer subcutaneous injections~* General good health otherwise~Exclusion Criteria:~* Prior anti-TNF therapy~* Unstable antibiotic therapy for HS~* Required medication washouts for other HS treatments~* Prior exposure to Tysabri® (natalizumab);~* Recent infection requiring treatment~* Significant medical events or conditions that may put patients at risk for participation~* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;~* History of cancer, except successfully treated skin cancer~* Recent history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab 40 mg qwk (Type: EXPERIMENTAL): Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
- Adalimumab 40 mg eow (Type: EXPERIMENTAL): Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).